The Effect of Therapy With Bevacizumab in Chronic Central Serous Chorioretinopathy

Not Applicable

• Conditions: Central Serous Chorioretinopathy

• Registration Number: NCT00864773
• Lead Sponsor: Hallym University Medical Center

Brief Summary

The pathophysiology of central serous chorioretinopathy remains controversial. traditional treatment is laser photocoagulation or photodynamic therapy.Recently Bevacizumab (Avastin, Genetech),an antibody to vascular endothelial growth factor (VEGF),has known antipermeability properties and therefore may theoretically reverse the changes seen in central serous chorioretinopathy. The aim of this study is To investigate concentrations of growth factors and inflammatory cytokines and to report the effect of therapy with bevacizumab in eyes with central serous chorioretinopathy

Detailed Description

Not available

Study Timeline

• Status Verified: 2009-03
• Study Start: 2009-03
• Study First Submitted: 2009-03-18
• Study First Submitted QC: 2009-03-18
• Last Update Submitted: 2009-03-18
• Study First Posted: 2009-03-19
• Last Update Posted: 2009-03-19
• Primary Completion: 2010-03
• Study Completion: 2010-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Patients with a diagnosis of central serous chorioretinopathy
• Idiopathic neurosensory retinal elevation demonstrated by optical coherent tomography
• Presence of focal leaks at the level of the RPE on fluorescein angiography

Exclusion Criteria

• Known side effects of systemic bevacizumab administration
• Have a significant cardiovascular or thromboembolic history or were pregnant

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Concentrations of growth factors and inflammatory cytokines in Aqueous humor	at baseline

Secondary Outcome Measures

Name	Time	Method
Central macular thickness at optical coherence tomography	baseline, 1 month, 3 months, 6 months